Amorfix Life Sciences

  • 3403 American Drive, Mississauga,
  • Ontario, Canada, L4V 1T4
  • Tel: 416-847-6898 info@amorfix.com
  • Home
  • Letter From The CEO
  • Company
    • Management
    • Board of Directors
  • Products
    • Product Pipeline
    • Diagnostics
      • Alzheimer's Disease Dx
      • ALS
      • Liver Cancer
    • Therapeutics
      • ALS
      • Cancer
  • Technologies
    • Epitope Protection
    • ProMIS™ and DSE
  • Services
    • A4
    • Assay Development
  • Investor Relations
    • Press Releases 2013
      • 2012
      • 2011
      • 2010
      • 2009
      • 2008
      • 2007
      • 2006
      • 2005
    • In the News
    • Events
    • Financial Results
      • 12-13
      • 11-12
      • 10-11
      • 09-10
      • 08-09
      • 07-08
  • Careers
  • Contact
receive news alerts

PRESS RELEASE

Press release 2013

Press release 2012

Press release 2011

Press release 2010

Press release 2009

Press release 2008

Press release 2007

Press release 2006

Press release 2005



April 25, 2013 Amorfix to investigate lung cancer misfolded proteins for therapeutic intervention
April 22, 2013 Amorfix closes second tranche of private placement offering
April 9, 2013 Amorfix announces breakthrough scientific discovery and provides update for its ovarian cancer therapeutic antibody program
April 5, 2013 Amorfix closes private placement offering
April 3, 2013 Amorfix chief science officer to present latest on ovarian cancer therapeutic program at AACR 2013
March 20, 2013 Amorfix announces progress on ALS program
February 21, 2013 Amorfix closes private placement offering
February 14, 2013 Amorfix announces third quarter fiscal 2013 results and financing
January 31, 2013 Pharmaceutical executive Warren Whitehead joins Amorfix as chief financial officer
January 29, 2013 Amorfix and QPS to collaborate on Alzheimer's disease project
January 24, 2013 Amorfix to present cancer therapeutic program at AACR 2013
January 22, 2013 Amorfix provides update on ALS diagnostic program
January 4, 2013 Amorfix to present corporate overview at the Biotech Showcase 2013 Conference
  • Home
  • Letter From The CEO
  • Company
    • Management
    • Board of Directors
  • Products
    • Product Pipeline
    • Alzheimer's Disease
    • ALS Diagnostic
    • ALS Therapeutics
    • Cancer Therapeutics
  • Technologies
    • Epitope Protection
    • ProMIS™ and DSE
  • Services
    • A4
    • Assay Development
  • Investor Relations
    • Press Releases
    • In the News
    • Events
    • Financial Results
  • Careers
  • Contact